The drug for heart diseases of Bristol Myers did not justify itself

Bristol Myers, designed to deliver patients, did not show results from some heart disease, at the later stages of testing the results.

The drug «Mavakamet» was tested on adult patients with the so-called non-constructive form of hypertrophic cardiomyopathy, Xrust said. This is a hereditary disease expressed by a thickening of the heart muscle.

Experts claim that this disease affects every fifth adult in the world and is the most common cause of sudden heart death among healthy young people in the United States.

The drug under the camzyos trademark is already approved in the United States to treat a more severe, obstructive form of the disease that can block blood outflow from the heart.

pharmacists noted that the research of the study reflects the difficulty of A demonstration of advantages in less severe groups of patients. The manufacturer of the drug said that during the study no new security signals were revealed.

580 patients with a symptomatic uncompensated GKMP took part in the study. Patients were asked to fill out a clinical questionnaire to assess their health, including the frequency of symptoms, physical and social restrictions.